Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

Table 1

Characteristics of the unpublished and undisclosed studies.

Study	Number of patients planned	Comparator	Add-on to	Trial duration (wks)	Design	Study end date*	Sponsor
Exenatide
NCT00434954	488	Aspart	Metformin	26	PS, DB	August 2009	Amylin
Liraglutide
NCT00696657	415	Placebo	None	12	PS, DB	February 2009	Novo
Taspoglutide
NCT00809705	60	Placebo	None	12	PS, DB	February 2010	Hoff-Roche

PS: parallel series; DB: double blind; Hoff. Roche: Hoffman-La Roche; Novo: Novo Nordisk.